Preclinical enzyme replacement therapy with a recombinant -galactosidase-lectin fusion for CNS delivery and treatment of GM1-gangliosidosis

GM1-gangliosidosis is a catastrophic, neurodegenerative lysosomal storage disease caused by a deficiency of lysosomal beta-galactosidase (beta-Gal). The primary substrate of the enzyme is GM1-ganglioside (GM1), a sialylated glycosphingolipid abundant in nervous tissue. Patients with GM1-gangliosidosis present with massive and progressive accumulation of GM1 in the central nervous system (CNS), which leads to mental and motor decline, progressive neurodegeneration, and early death. No therapy is currently available for this lysosomal storage disease. Here, we describe a proof-of-concept preclinical study toward the development of enzyme replacement therapy (ERT) for GM1-gangliosidosis using a recombinant murine beta-Gal fused to the plant lectin subunit B of ricin (m beta-Gal:RTB). We show that long-term, bi-weekly systemic injection of m beta-Gal:RTB in the beta-Gal(-/-) mouse model resulted in widespread internalization of the enzyme by cells of visceral organs, with consequent restoration of enzyme activity. Most importantly, beta-Gal( )activity was detected in several brain regions. This was accompanied by a reduction of accumulated GM1, reversal of neuroinflammation, and decrease in the apoptotic marker caspase 3. These results indicate that the RTB lectin delivery module enhances both the CNS-biodistribution pattern and the therapeutic efficacy of the beta-Gal ERT, with the potential to translate to a clinical setting for the treatment of GM1-gangliosidosis.